Introduction: Diabetic neuropathy is one of the most troublesome complications of diabetes which accounts for substantial morbidity. Thus, early identification and appropriate management of diabetic neuropathy is very important to reduce this burden. This study was done to identify the prevalence of diabetic peripheral neuropathy (DPN) and its impact on the patients' life and to assess the effectiveness of available treatment options.
Introduction
Longstanding diabetes is associated with complications in vital organs of the body. The disease, particularly when poorly controlled, affects the patient's neurological functions. Many studies have shown that almost 50% of individuals affected with diabetes are suffering from diabetic neuropathy. 1 DPN is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in patients with diabetes after excluding other causes of neurological dysfunction. 2 According to a review on diabetic polyneuropathy by Dyck et al, DPN is further subdivided into probable and possible DPN based on the presence of specific signs and symptoms. 3 
Objective
To assess the burden of diabetic peripheral neuropathy (DPN) and response to standard treatment regimens among diabetic clinic attendees in the Sri Jayewardenepura General Hospital in 2015.
Specific objectives
• To estimate the prevalence of DPN among patients attending the diabetic clinic 
Methodology
Study design: A cross-sectional descriptive study was conducted for a period of 15 weeks (15 clinic days) starting from 2nd April 2015. During the study period, a sample of 235 consecutive diabetic patients attending the clinic was selected for the study. Other causes which could lead to peripheral neuropathy were excluded by looking into their habits and past medical, surgical and drug history. Patients with dementia, Prevalence, burden and treatment response of diabetes peripheral neuropathy at the SJGH psychiatric disorders, and those unwilling to participate were excluded. To avoid duplicate entries each participant's clinic number was recorded.
Study Instrument: A pre-tes ted interviewer administered questionnaire and a check list were developed to assist the clinician to diagnose DPN. 4 The douleurneuropathique 4 (DN4) is a screening tool for neuropathic pain consisting of interview questions (DN4-interview) and physical tests. It was validated in Vergata University, Italy and reported a sensitivity of 90% and specificity of 83%.
5 DN4 was translated into Sinhala and Tamil languages to be used in this study, although yet not validated for the Sri Lankan setting as a whole. Tamil patients were interviewed by a Tamil speaking medical officer. Another interviewer administered questionnaire was used to assess the impact of neuropathy on their quality of life. The neuropathy and foot ulcer specific quality of life (NeuroQoL) was the study instrument. 6 An observation check list was also used to assess the effectiveness of treatment among the same patients.
Method of data collection: Questionnaire was pretested on 40 patients before commencing the proper research, to ensure the validity of the questionnaire. At the end of pretesting, the data collector discussed with the principal investigator and the necessary changes were made. Following pretesting, data were collected by a trained pre-intern medical officer and approximately 20 to 25 patients were interviewed per clinic session. At the first stage of the study, patients were interviewed for symptoms and examined for signs of DPN by the medical officer. All patients were subjected to comprehensive foot examination including the monofilament test, vibration and joint position sensation tests. Pin-prick sensation and light-touch perception were assessed using a 10g monofilament. The vibratory threshold was assessed using a 128 Hz tuning fork. In the second stage of the study, the interviewer administered questionnaire was introduced to the patients to assess the effect of neuropathy on their daily life and the perceived improvement of symptoms for the four pharmacologic treatment modalities (pregabalin, gabapentin, amitriptylin and duloxetine).
Ethical considerations:
Approval was obtained from the Ethics Committee of the Sri Jayewardenepura General Hospital. Informed written consent was obtained from all participants before administration of the questionnaire. Patients who refused to participate in the study were allowed to do so without requiring to give reasons for such refusal and they were assured that the services they were receiving from the clinic or hospital would not be affected in whatsoever manner. Confidentiality of the data was ensured and they were informed that the collected data will be used solely for research purposes.
Data analysis:
Statistical Package for Social Science (SPSS) version 20 was used for data entry and analysis. Data were cleaned and edited before detailed analysis was carried out. To assess the statistical significance in proportions between different groups Chi Square test and Fisher's exact test were applied, with the level of significance being 0.05. Table 1 describes the age and sex distribution of the study population. The male to female ratio of the study population was 1:1.86 (82: 153) and the majority (65%) were female.
Results
Age of the patients ranged from 30 to 80 years with a mean of 56 years. The proportion of DPN with clinical evidence by symptoms and signs among the 235 diabetics recruited was 174 (74%). Symptoms considered for the diagnosis of DPN were the characteristic symptoms of pain and the presence of current or previous neuropathic ulcers. While sensory deficit and the absence of ankle jerk were the signs considered; of the diagnosed 174 DPN patients, 97.1% were symptomatic. Table 2 shows the demographic characteristics and factors associated with DPN among patients with diabetes attending the dedicated clinic. The data show an increasing trend of DPN with age. While 63% of diabetics below the age of 50 years had DPN, 86% of affected patients with diabetes above the age of 60 years had DPN, which is statistically significant (p<0.01). There was no significant association of DPN Of the 174 DPN patients detected by this survey, only 48 (27.6%) were on treatment with specific pharmacotherapy drugs (Table 5 ). Drugs prescribed were pregabalin, gabapentin, amitriptylin and duloxetine in 25(52.1%), 16(33.3%), 3(6.3%) and 4(8.3%) respectively. The different treatment regimens for individual patient were decided by the treating physician on par with available guidelines. Table 5 shows the reported improvement of symptoms with the differing treatment options, irrespective of the drug regimen and duration of treatment. Among the treated patients 34 (73.9%) reported an improvement. The improvement with the different drugs is also depicted in Table 6 . Since the numbers involved were small, any association between different drugs and improvement status could not be statistically tested. The proportion that reported an improvement within 6 months and beyond 6 months of therapy were 73.7 and 76.0 and not significantly different. Table 6 . Reported symptomatic improvement based on the duration of treatment
Characteristic

Discussion
The prevalence of DPN in newly diagnosed patient with diabetes is estimated to be 8% and greater than 50% in patient with long standing disease. 7 In our study, the prevalence of DPN was 74%, of whom 5.2% had a duration of diabetes less than one year. Thirty four percent had diabetes for less than five years. These relatively higher values may be due to ethnic differences of the study sample. Yet another possibility is that these patients had undiagnosed and untreated diabetes for a long period. Therefore we should aim to strengthen our screening programmes, of at least among high risk population, and in particular ensure improved glycaemic control within the first five years since the detection of diabetes. A previous Sri Lankan study carried out in the community reported that the prevalence of DPN was much lower than our finding. 7 This difference may be due to the fact that our study is confined to a tertiary hospital based clinic. Several epidemiological studies have shown that the duration and severity of diabetes (assessed by glycated haemoglobin) are significant risk factors for the development of DPN. 9 Our study also showed that the duration of diabetes is a significant risk factor.
Symptoms such as burning, tingling, numbness, shooting (electric shock) and stabbing sensations are present in 33% of patients with DPN according to some studies. 10, 11 Our study found that 63.8% complained of numbness, 34.5% complained of burning pain and 42.5% of patients complained of a pricking type of pain in their soles. We found that 68.4% of the cohort 12 We also detected that 43.7% of patients had sleep disturbances due to their neuropathic symptoms.
Although there is no treatment currently available to repair the nerve damage of DPN, there is effective symptomatic treatment available for the relief of symptoms associated with DPN. Several randomized placebo controlled trials have shown the effectiveness of tricyclic anti-depressants in the treatment of painful diabetic neuropathy. 13, 14 Serotonin -noradrenaline reuptake inhibitors have also been shown to be effective for painful diabetic neuropathy, e.g. venlafaxine and duloxetine. 15, 16 . In an eight week, multicenter randomized controlled trial of 165 patients with DPN, gabapentin was reported to give moderate pain relief when compared with placebo. 17 In a pooled analysis from 7 randomized, placebo-controlled trials pregabalin was shown to relieve pain and improve the quality of life, measures of social functioning and mental health as well as to improve sleep.
18
The affected patients who received such treatment in this study also reported a good response to them. Three quarters of the affected group responded to the treatment prescribed. Patients prescribed pregabalin, reported a good response in 78.26% while 68.75% of the group prescribed gabapentin said that they had satisfactory response.
Conclusion
The prevalence of diabetic peripheral neuropathy is high in this study. Symptomatic DPN can affect the life of the person to a considerable degree. The currently available treatment give good symptomatic relief. Regular screening programmes are recommended to strengthen early detection of undiagnosed cases with a view to prevention of such complications of diabetes.
